GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine

Giant cell vasculitis post-COVID-19 mRNA vaccine and COVID-19 asymptomatic infection: Correspondence

The possible adverse effect of COVID-19 vaccine is interesting. This correspondence discussed on the case of Giant cell vasculitis post-COVID-19 mRNA vaccine. The possible effect of the COVID-19 asymptomatic infection is highlighted.

SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: correspondence

We would like to discuss "Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis". The serological responses, breakthrough infections, and clinical relapse of IBD patients treated with biological drugs after SARS-CoV-2 immunization were the subject of a thorough study and meta-analysis. The total seroconversion rate following SARS-CoV-2 immunization in IBD patients receiving biological therapy is high, according to Dai et al. In IBD patients receiving biological therapy, the overall rate of breakthrough infections and the rate of clinical recurrence were both low.

Influence of the Single Nucleotide Polymorphisms rs12252 and rs34481144 in IFITM3 on the Antibody Response after Vaccination against COVID-19

The COVID-19 mRNA vaccine is the first mRNA vaccine approved for human administration by both the U.S. Food and Drug Administration and the European Medicines Agency. Studies have shown that the immune response and the decay of immunity after vaccination with the COVID-19 vaccines are variable within a population. Host genetic factors probably contribute to this variability. In this study, we investigated the effect of the single-nucleotide polymorphisms rs12252 and rs34481144 in the interferon-induced transmembrane protein (IFITM) 3 gene on the humoral immune response after vaccination against COVID-19 with mRNA vaccines. Blood samples were collected from 1893 healthcare workers and medical students at multiple time points post-vaccination and antibody titers against the SARS-CoV-2 S1 protein receptor binding domain were determined at all time points. All participants were genotyped for the rs34481144 and rs12252 polymorphisms in the IFITM3 gene. After the second and third vaccinations, antibody titer levels increased at one month and decreased at six months (p < 0.0001) and were higher after the booster vaccination than after the basic immunization (p < 0.0001). Participants vaccinated with mRNA-1273 had a higher humoral immune response than participants vaccinated with BNT162b2. rs12252 had no effect on the antibody response. In contrast, carriers of the GG genotype in rs34481144 vaccinated with BNT162b2 had a lower humoral immune response compared to A allele carriers, which reached statistical significance on the day of the second vaccination (p = 0.03) and one month after the second vaccination (p = 0.04). Further studies on the influence of rs12252 and rs34481144 on the humoral immune response after vaccination against COVID-19 are needed.